Leerink Partnrs Estimates Xeris Biopharma FY2025 Earnings

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) – Equities researchers at Leerink Partnrs issued their FY2025 earnings estimates for Xeris Biopharma in a report released on Wednesday, June 4th. Leerink Partnrs analyst R. Ruiz expects that the company will post earnings per share of ($0.05) for the year. The consensus estimate for Xeris Biopharma’s current full-year earnings is ($0.41) per share. Leerink Partnrs also issued estimates for Xeris Biopharma’s FY2026 earnings at $0.10 EPS and FY2027 earnings at $0.30 EPS.

XERS has been the topic of a number of other reports. Wall Street Zen cut Xeris Biopharma from a “buy” rating to a “hold” rating in a research note on Thursday, May 22nd. Piper Sandler reaffirmed a “neutral” rating and set a $4.00 target price (up from $3.00) on shares of Xeris Biopharma in a report on Friday, March 7th. Craig Hallum lifted their target price on Xeris Biopharma from $5.00 to $6.50 and gave the stock a “buy” rating in a report on Friday, March 7th. HC Wainwright restated a “buy” rating and issued a $8.00 price target (up previously from $6.60) on shares of Xeris Biopharma in a research report on Friday, March 7th. Finally, Leerink Partners lifted their target price on Xeris Biopharma from $5.00 to $6.00 and gave the company an “outperform” rating in a research note on Friday, March 7th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $6.25.

Xeris Biopharma Price Performance

Shares of XERS opened at $4.58 on Monday. The business’s fifty day moving average price is $4.56 and its 200 day moving average price is $4.09. Xeris Biopharma has a 12-month low of $2.03 and a 12-month high of $6.07. The stock has a market capitalization of $716.24 million, a PE ratio of -10.18 and a beta of 0.71.

Xeris Biopharma (NASDAQ:XERS) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.01. The firm had revenue of $57.80 million during the quarter, compared to analyst estimates of $57.61 million.

Insider Buying and Selling at Xeris Biopharma

In other news, insider Beth Hecht sold 40,000 shares of the stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $5.43, for a total transaction of $217,200.00. Following the sale, the insider now owns 1,353,510 shares in the company, valued at approximately $7,349,559.30. This represents a 2.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 6.47% of the company’s stock.

Institutional Trading of Xeris Biopharma

Several large investors have recently made changes to their positions in XERS. Nuveen LLC acquired a new position in shares of Xeris Biopharma during the first quarter valued at $12,240,000. Parkman Healthcare Partners LLC lifted its stake in shares of Xeris Biopharma by 207.8% during the first quarter. Parkman Healthcare Partners LLC now owns 1,780,454 shares of the company’s stock valued at $9,775,000 after acquiring an additional 1,201,943 shares during the period. Goldman Sachs Group Inc. lifted its stake in shares of Xeris Biopharma by 75.4% during the first quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock valued at $15,317,000 after acquiring an additional 1,199,435 shares during the period. Invesco Ltd. lifted its stake in shares of Xeris Biopharma by 1,387.8% during the first quarter. Invesco Ltd. now owns 1,026,838 shares of the company’s stock valued at $5,637,000 after acquiring an additional 957,822 shares during the period. Finally, Driehaus Capital Management LLC lifted its stake in shares of Xeris Biopharma by 137.6% during the first quarter. Driehaus Capital Management LLC now owns 1,411,540 shares of the company’s stock valued at $7,749,000 after acquiring an additional 817,525 shares during the period. Institutional investors own 42.75% of the company’s stock.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.